Zoonoses

Cocrystal Pharma Reports First Quarter 2021 Financial Results and Provides Business Update

Monday, May 17, 2021 - 1:00pm

\xe2\x80\x9cAs discussed in our coronavirus update release earlier this month, we continue developing novel SARS-CoV-2 oral protease inhibitors and are rapidly advancing lead compounds.

Key Points: 
  • \xe2\x80\x9cAs discussed in our coronavirus update release earlier this month, we continue developing novel SARS-CoV-2 oral protease inhibitors and are rapidly advancing lead compounds.
  • That agreement provides Cocrystal with an exclusive, royalty-bearing license to develop and commercialize therapeutic, diagnostic and prophylactic products against coronaviruses, caliciviruses and picornaviruses based on antivirals discovered by KSURF.
  • The Company believes the 3CL protease has the ability to convert the inactive SARS-CoV-2 replication enzymes into the active form.
  • As anticipated, Cocrystal reported no revenues for the first quarter of 2021 compared with $461,000 in revenues for the first quarter of 2020.

Worldwide Genomics Industry to 2026 - Widening Range of Applications of Genomics and Government Support is Driving Growth - ResearchAndMarkets.com

Monday, May 17, 2021 - 10:10am

As per the annual report of 2020 by Nanostring Technologies Inc., the company witnessed a massive decline of 18% in its Consumables segment compared to 2019.

Key Points: 
  • As per the annual report of 2020 by Nanostring Technologies Inc., the company witnessed a massive decline of 18% in its Consumables segment compared to 2019.
  • According to the 2020 results published by 10X Genomics Inc., the company observed a decline of 23.0% compared to 2019.
  • However, the situation is found to be improving gradually.\nConsumables accounted for a significant share of the genomics market.
  • In August 2020, Eurofins Technologies launched reagents for automated isolation of high-quality SARS-CoV-2 RNA from viral particles of human respiratory specimens.

Memo Therapeutics AG Antibodies Against SARS-CoV-2 Show Efficacy Against British and South African Variant

Monday, May 17, 2021 - 8:00am

b'Memo Therapeutics AG (\xe2\x80\x9cMemo\xe2\x80\x9d), an innovator in the field of antibody discovery and development, announced today that MTX-COVAB, its human-derived antibody against SARS-CoV-2, the virus that causes COVID-19, has shown efficacy against both the original virus as well as the UK variant (B.1.1.7).

Key Points: 
  • b'Memo Therapeutics AG (\xe2\x80\x9cMemo\xe2\x80\x9d), an innovator in the field of antibody discovery and development, announced today that MTX-COVAB, its human-derived antibody against SARS-CoV-2, the virus that causes COVID-19, has shown efficacy against both the original virus as well as the UK variant (B.1.1.7).
  • Memo is now preparing MTX-COVAB for clinical evaluation.\nUsing its microfluidic, single-cell molecular cloning and screening technologies to enable antibody repertoire mining and antibody discovery, Memo can discover novel antibodies at unprecedented speed, efficiency and sensitivity derived from recovered patient samples.
  • This can be achieved in as little as 3 weeks from receiving the blood sample.\n\xe2\x80\x9cAddressing SARS-CoV-2 variants remains a global challenge and one that will remain.
  • Memo Therapeutics AG is a private company located in Bio-Technopark Zurich, Switzerland.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210517005220/en/\n'

Six in 10 Parents Plan to Vaccinate All of Their Children and Large Majority of Parents Would Feel Safer Sending Kids to School if Most Other Children Were Vaccinated

Monday, May 17, 2021 - 5:01am

Vaccination intent in parents varies across racial and ethnic groups, with Asian American and Pacific Islander parents being the most likely to vaccinate their children (77%) and Black parents being the least likely (55%).

Key Points: 
  • Vaccination intent in parents varies across racial and ethnic groups, with Asian American and Pacific Islander parents being the most likely to vaccinate their children (77%) and Black parents being the least likely (55%).
  • And while at least 65% of parents of children ages six to 17 plan to vaccinate their children, only 56% of parents of children under the age of six will vaccinate their children.\nVaccination intent is especially prevalent in conversations about children returning to school.
  • Parents also fear the risk of the virus to their children.
  • 70% of parents are worried that their children could get COVID-19 and view protecting their children as an important reason to vaccinate their children (83%) and themselves (77%).

Oxford University and Oracle Partner to Speed Identification of COVID-19 Variants

Monday, May 17, 2021 - 12:01am

To help governments and medical communities identify and act on these variants faster, Oxford University and Oracle have created aGlobal Pathogen Analysis System (GPAS) combining Oxford\'s Scalable Pathogen Pipeline Platform ( SP3 ) with the power of Oracle Cloud Infrastructure (OCI).

Key Points: 
  • To help governments and medical communities identify and act on these variants faster, Oxford University and Oracle have created aGlobal Pathogen Analysis System (GPAS) combining Oxford\'s Scalable Pathogen Pipeline Platform ( SP3 ) with the power of Oracle Cloud Infrastructure (OCI).
  • The SP3system will now deliver comprehensive and standardized results of COVID-19 analyses within minutes of submission on an international scale.
  • This includes identifying variants of interest and their potential impact on vaccine and treatmenteffectiveness.
  • As new variants of SARS-CoV-2 emerge around the world, it requires a cooperative global effort to respond effectively.

Researchers Show How COVID-19 Virus Triggers Immune Signaling "Storm"

Friday, May 14, 2021 - 7:21pm

The virus evolved to have a protein spike that snags ACE2 as the first step in invading human lung cells, where the virus multiplies.

Key Points: 
  • The virus evolved to have a protein spike that snags ACE2 as the first step in invading human lung cells, where the virus multiplies.
  • Accordingly, all approved COVID-19 antiviral drugs and vaccines work by interfering with, or protecting against, this viral spike/ACE2 interaction.\nMounting evidence, however, suggests that the virus also interacts directly with human immune cells, which have little ACE2 on their surfaces.
  • Five were C-type lectins, carbohydrate-binding protein units with many biological functions, including in immune defenses.
  • Nanobodies are smaller derivatives of antibodies, immune proteins that form a surveillance system by recognizing invading microbes.

aTyr Pharma Announces First Quarter 2021 Results and Provides Corporate Update

Thursday, May 13, 2021 - 9:05pm

Our manufacturing agreement with Lonza for the production of this antibody reflects our commitment to this program.

Key Points: 
  • Our manufacturing agreement with Lonza for the production of this antibody reflects our commitment to this program.
  • Data is expected in the third quarter of this year.\nReported positive results from its Phase 2 study of ATYR1923 in COVID-19 patients with severe respiratory complications, which provided proof-of-mechanism for ATYR1923.
  • Research and development expenses were $4.5 million and $3.6 million for the three months ended March 31, 2021 and 2020, respectively.
  • Links to a live audio webcast and replay may be accessed on the aTyr website events page at: http://investors.atyrpharma.com/events-and-webcasts.

ISHLT and JHLT Share COVID-19 Vaccination Findings and Recommendations

Thursday, May 13, 2021 - 6:41pm

b'ADDISON, Texas, May 13, 2021 /PRNewswire/ -- Evidence is emerging about the immunogenicity of vaccination to the SARS-CoV-2 virus in immune-suppressed individuals, including organ transplant recipients.

Key Points: 
  • b'ADDISON, Texas, May 13, 2021 /PRNewswire/ -- Evidence is emerging about the immunogenicity of vaccination to the SARS-CoV-2 virus in immune-suppressed individuals, including organ transplant recipients.
  • Vaccination was safe with no evidence of short-term allograft-related adverse effects in either cohort.
  • "We also encourage the continued SARS-CoV-2 vaccination of SOT recipients and priority for vaccination of their household members and caregivers to reduce exposure risk for these vulnerable patients.
  • Importantly, the Journal also serves as a medium of communication of pre-clinical sciences in all these rapidly expanding areas.

Cov Clinic Helps Open Schools and Summer Camps

Thursday, May 13, 2021 - 11:00am

One of their primary efforts provides Free testing and eventually offer vaccinations to schoolsin San Diego county.

Key Points: 
  • One of their primary efforts provides Free testing and eventually offer vaccinations to schoolsin San Diego county.
  • They facilitate a seamless pre-registration process for students prior to the first day of testing.
  • The company plans to provide their services across the west coast and eventually nationwide.\nAbout Cov Clinic LLC:Cov Clinic is a Covid-19 testing company based in Las Vegas, NV.
  • Founded in 2020, Cov Clinic was formed with the goal of giving an optimal patient experience.

IMM124E – May offer a New modality for Inhibition of SARS-CoV-2

Thursday, May 13, 2021 - 11:00am

Different studies have demonstrated the existence of cross-reactive immunity through shared sites/epitopes between the bovine and human viruses.

Key Points: 
  • Different studies have demonstrated the existence of cross-reactive immunity through shared sites/epitopes between the bovine and human viruses.
  • Thus, it appears that the immunological homology in highly conserved structures between the two viruses may be the cause of the reported inhibition.
  • Dr Peres will be responsible for leading and managing the company\xe2\x80\x99s clinical development programs with a preliminary focus on COVID-19.
  • Dr Peres was previously engaged by Immuron to manage the company sponsored NASH phase II clinical trial.\nThis release has been authorised by the directors of Immuron Limited.\n'